Dodecafluoropentane emulsion (DDFPE), NANO2? As cerebroprotectant in ischemic stroke
Ended Cooperative Agreement Awarded Last action
- Award ID
- U44NS130589
- Recipient
-
Nuvox Pharma, L.L.C. UEI WHNYG96UDLJ8
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,501,161
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date
- Place of performance
- Tucson, AZ 85719, USA
Award details come from USAspending.gov.
Description
- Abstract
- / project summary stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and TPA, has emerged as standard of care treatment of LVO stroke. Up to 60% of thrombectomy patients are first evaluated at spoke hospitals and transferred to hub hospitals for MT. `time is brain' following stroke, the sooner therapy can be instituted, the greater the likelihood of preserving neurological function. A therapy that could be rapidly deployed in all stroke patients to preserve the brain could provide enormous potential benefit to stroke patients. NANO2TM (AKA dodecafluoropentane emulsion, ddfpe) significantly decreased stroke volume (SV), by about 85%, and improved neurological assessment score (NAS) in rabbits when administered IV up to 3 hours following stroke and also improved SV and NAS in permanent RAT mcao. In a randomized, placebo-controlled phase IB/II clinical trial of acute ischemic stroke, in which patients receive standard reperfusion therapy, NANO2 was safe at all dose levels. The higher doses of NANO2 caused significantly better modified rankin scale (MRS) at 30 and 90-days post stroke. Early administration of NANO2 (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $299,943 | |
| Amendment | $299,243 | |
| Amendment | $299,243 | |
| Amendment | $301,366 | |
| Original award | $301,366 |
Quick answers
Who received award U44NS130589?
U44NS130589 was awarded to Nuvox Pharma, L.L.C. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on April 15, 2023.
How much is award U44NS130589 worth?
$1,501,161 has been obligated on U44NS130589.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award